Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients; histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110–124
2. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S, Baselga J (2003) ZD1839, a specific epidermal growth factor receptor (EFGR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274–1283
3. Arteaga CL (2003b) ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284: 122–130
4. Arteaga CL (2003a) Targeting HER/EGFR; a molecular approach to cancer therapy. Semin Oncol 30(Suppl 7): 3–14
5. Bianco R, Shin I, Ritter Ca, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis Pa, Mills GB, Arteaga CL (2003) Loss of PTEN.MMAC1/TEP in EGF receptor expressing tumour cells counteracts the antitumour action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812–2822
Cited by
104 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献